All In Biotech

Drug Trial Radar · NCT07476729

International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)

International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 A Randomized Phase III Study Conducted by the Resistant Disease Committee of the International BFM Study Group

Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 750 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

750

Planned (sponsor's estimate)

Start

Sep 1, 2026

Primary completion

Mar 31, 2033

Study completion Mar 31, 2033

Sponsor

Lead sponsor
Charite University, Berlin, GermanyAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 1 year
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The IntReALL BCP 2020 study aims to review recent developments and findings regarding chemoimmunotherapy with inotuzumab and immunotherapy with blinatumomab and to increase the use of promising new immunotherapeutic drugs as replacements for toxic SOC chemotherapy elements. The IntReALL BCP 2020 study has the potential to improve CR and EFS rates for all SR and HR groups, as well as for patients with IEM recurrence, by replacing toxic chemotherapy with targeted, less toxic immunotherapy strategies, and could establish these new approaches as SOC for children with relapsed BCP ALL in the future.

Conditions

  • B-Cell Acute Lymphoblastic Leukaemia

Interventions

  • Inotuzumab ozogamicin (INO)Drug

    Antibody Drug Conjugate (Inotuzumab)

  • BlinatumomabDrug

    Bispecific t-cell enganger BiTE

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. SR induction EFSTime frame: From enrollment until 2 years after end of treatment
  2. SR-MRD good response consolidation DFSTime frame: From enrollment until 2 years after end of treatment
  3. HR with CR2 consolidation DSFTime frame: From enrollment until 2 years after end of treatment
  4. Isolated extramedullary manifestations: EFSTime frame: From enrollment until 2 years after end of treatment
  5. SR induction: Pharmacokinetics InotuzumabTime frame: from enrollment until day 28

Locations

21 sites in 21 countries. Site status is shown where the registry gives one.

  • St. Anna Kinderspital GmbH

    Vienna, Austria · Recruiting

  • Ghent University Hospital

    Ghent, Belgium · Not yet recruiting

  • Fakultni Nemocnice V Motole

    Prague, Czechia · Recruiting

  • Rigshospitalet

    Copenhagen, Denmark · Recruiting

  • HUS Helsinki University Hospital

    Helsinki, Finland · Not yet recruiting

  • CHU de NICE, Hôpital L'ARCHET

    Nice, France · Recruiting

  • Charité - Universitätsmedizin Berlin

    Berlin, Germany · Recruiting

  • Semmelweis University

    Budapest, Hungary · Not yet recruiting

  • Tel Aviv Sourasky Medical Centre Dana-Dwek Children's Hospital

    Tel Aviv, Israel · Not yet recruiting

  • Ospedale Pediatrico Bambino Gesu

    Rome, Italy · Not yet recruiting

  • Prinses Máxima Centrum

    Utrecht, Netherlands · Recruiting

  • Oslo University Hospital

    Oslo, Norway · Recruiting

  • University Wroclaw

    Wroclaw, Poland · Not yet recruiting

  • Instituto Português de Oncologia de Lisboa

    Lisbon, Portugal · Not yet recruiting

  • Fundeni Clinical Institute, Pediatric Clinic Fundeni

    Bucharest, Romania · Not yet recruiting

  • Univerzity Komenského a Národného

    Bratislava, Slovakia · Not yet recruiting

  • University Medical Centre Ljubljana

    Ljubljana, Slovenia · Not yet recruiting

  • University Clinical Hospital Virgen De La Arrixaca

    Murcia, Spain · Recruiting

  • Karolinska University Hospital

    Solna, Sweden · Recruiting

  • University Children's Hospital

    Zurich, Switzerland · Not yet recruiting

  • Acıbadem University

    Istanbul, Turkey (Türkiye) · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.